Company announces new data analysis from multiple Phase 2 and 3 studies of the long-term efficacy of nusinersen (Spinraza) therapy in spinal muscular atrophy (SMA)

In NURTURE study (n=25) 92% of children who initiated treatment as pre-symptomatic infants’ maintained swallow ability after ~4 years. Children & teens with later-onset SMA in the SHINE study (n=14), long-term treatment improved walking distance and reduced fatigue.

Biospace Inc.